{"id":353601,"date":"2010-02-23T11:51:11","date_gmt":"2010-02-23T16:51:11","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=64707"},"modified":"2010-02-23T11:51:11","modified_gmt":"2010-02-23T16:51:11","slug":"proacta-raises-1-1m","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/353601","title":{"rendered":"ProActa Raises $1.1M"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/cancer\/\">cancer<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/funding\/\">funding<\/a><\/div>\n<p>\t\t<strong>Bruce V. Bigelow wrote:<\/strong><\/p>\n<p><a href=\"http:\/\/www.proacta.com\/about\/\">ProActa<\/a>, which is developing an anti-cancer drug transplanted from New Zealand, has raised $1.1 million in debt and securities, according to a recent regulatory <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1297823\/000129782310000004\/xslFormDX01\/primary_doc.xml\">filing<\/a>. The biotech, which has raised at least $43 million in venture funding since 2004, announced earlier this month that it was starting a second mid-stage clinical trial of a drug for Acute Myeloid Leukemia. ProActa&#8217;s investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital of New Zealand, GBS Venture Partners of Australia, Genentech, No. 8 Ventures of New Zealand, and Roche.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/02\/23\/proacta-raises-1-1m\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20ProActa%20Raises%20$1.1M%20http:\/\/xconomy.com\/?p=64707\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/san-diego\/2010\/02\/23\/proacta-raises-1-1m\/&#038;t=ProActa%20Raises%20$1.1M\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/san-diego\/2010\/02\/23\/proacta-raises-1-1m\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=ProActa+Raises+%241.1M&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fsan-diego%2F2010%2F02%2F23%2Fproacta-raises-1-1m%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=c4ec7c87a10374491fa93df4ed29f145&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=c4ec7c87a10374491fa93df4ed29f145&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/Z4W1Wl9HxvK5iVgo9k7T2q1Mgtw\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/Z4W1Wl9HxvK5iVgo9k7T2q1Mgtw\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/Z4W1Wl9HxvK5iVgo9k7T2q1Mgtw\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/Z4W1Wl9HxvK5iVgo9k7T2q1Mgtw\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/ZfUpl3C7Zww\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Life Sciences, cancer, funding Bruce V. Bigelow wrote: ProActa, which is developing an anti-cancer drug transplanted from New Zealand, has raised $1.1 million in debt and securities, according to a recent regulatory filing. The biotech, which has raised at least $43 million in venture funding since 2004, announced earlier this month that it was starting [&hellip;]<\/p>\n","protected":false},"author":5423,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-353601","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/5423"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=353601"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353601\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=353601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=353601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=353601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}